This is a working overview of incretin hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C187H291N45O59 | 按主链与 C18 二酸侧链计算 |
| 分子量 | 约 4113.6 道尔顿 | 游离碱形式，随反离子略有差异 |
| 外观 | 白色至类白色冻干粉末 | 具吸湿性，需干燥保存 |
| 溶解性 | 微溶于水，易溶于碱性缓冲液 | 溶解性随 pH 升高而改善 |
| 等电点 | 约 5.4 | 影响缓冲液选择与聚集倾向 |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Deoxyribozymes, also called DNAzymes or catalytic DNA, were first discovered in 1994. They are mostly single stranded DNA sequences isolated from a large pool of random DNA sequences through a combinatorial approach called in vitro selection or systematic evolution of ligands by exponential enrichment (SELEX). DNAzymes catalyze variety of chemical reactions including RNA-DNA cleavage, RNA-DNA ligation, amino acids phosphorylation-dephosphorylation, carbon-carbon bond formation, etc. DNAzymes can enhance catalytic rate of chemical reactions up to 100,000,000,000-fold over the uncatalyzed reaction. The most extensively studied class of DNAzymes is RNA-cleaving types which have been used to detect different metal ions and designing therapeutic agents. Several metal-specific DNAzymes have been reported including the GR-5 DNAzyme (lead-specific), the CA1-3 DNAzymes (copper-specific), the 39E DNAzyme (uranyl-specific) and the NaA43 DNAzyme (sodium-specific). The NaA43 DNAzyme, which is reported to be more than 10,000-fold selective for sodium over other metal ions, was used to make a real-time sodium sensor in cells.
In 1940, penicillin became available for medicinal use to treat bacterial infections in humans. The field of modern biotechnology is generally thought of as having been born in 1971 when Paul Berg's (Stanford) experiments in gene splicing had early success. Herbert W. Boyer (Univ. Calif. at San Francisco) and Stanley N. Cohen (Stanford) significantly advanced the new technology in 1972 by transferring genetic material into a bacterium, such that the imported material would be reproduced. The commercial viability of a biotechnology industry was significantly expanded on June 16, 1980, when the United States Supreme Court ruled that a genetically modified microorganism could be patented in the case of Diamond v. Chakrabarty. Indian-born Ananda Chakrabarty, working for General Electric, had modified a bacterium (of the genus Pseudomonas) capable of breaking down crude oil, which he proposed to use in treating oil spills. (Chakrabarty's work did not involve gene manipulation but rather the transfer of entire organelles between strains of the Pseudomonas bacterium). The MOSFET was invented at Bell Labs between 1955 and 1960, Two years later, Leland C. Clark and Champ Lyons invented the first biosensor in 1962. Biosensor MOSFETs were later developed, and they have since been widely used to measure physical, chemical, biological and environmental parameters. The first BioFET was the ion-sensitive field-effect transistor (ISFET), invented by Piet Bergveld in 1970.
== Actin acts as a track for myosin motor motility == Myosin motors are intracellular ATP-dependent enzymes that bind to and move along actin filaments. Various classes of myosin motors have very different behaviors, including exerting tension in the cell and transporting cargo vesicles.
In 2008, Calderón signed the Mérida Initiative with the United States, which provided funding, training, and intelligence, and allowed U.S. personnel to operate in Mexico in advisory and intelligence-sharing capacities. By 2011, the Mexican Armed Forces had captured 11,544 people who were believed to have been involved with the cartels and organized crime. In the year prior, 28,000 individuals were arrested on drug-related charges. In October 2012, Mexican Navy forces killed Heriberto Lazcano, leader of Los Zetas, in a shootout in Sabinas, Coahuila, after gunmen attacked their patrol. The operation came just hours after the capture of another senior Zeta, Salvador Alfonso Martínez Escobedo. Lazcano's death is viewed as the most significant cartel leader killing in Calderón's administration. It strengthened the Navy's standing, allowed Miguel Treviño Morales to take control of Los Zetas, and ultimately benefited Joaquín "El Chapo" Guzmán, whose Sinaloa Cartel sought to dominate the Nuevo Laredo smuggling routes.
Sources: en.wikipedia.org
=== Cardiovascular === MMP9 levels increase with the progression of idiopathic atrial fibrillation. MMP9 has been found to be associated with the development of aortic aneurysms, and its disruption prevents the development of aortic aneurysms. Doxycycline suppresses the growth of aortic aneurysms in animal models through its inhibition of MMP9 reduces aortic inflammation in humans.
== Signs and symptoms == Individuals with Stickler syndrome experience a range of signs and symptoms. Some people have no signs and symptoms; others have some or all of the features described below. In addition, each feature of this syndrome may vary from subtle to severe. A characteristic feature of Stickler syndrome is a somewhat flattened facial appearance. This is caused by underdeveloped bones in the middle of the face, including the cheekbones and the bridge of the nose. A particular group of physical features, called the Pierre Robin sequence, is common in children with Stickler syndrome. Pierre Robin sequence includes a U-shaped or sometimes V-shaped cleft palate (an opening in the roof of the mouth) with a tongue that is too large for the space formed by the small lower jaw. Children with a cleft palate are also prone to ear infections and occasionally swallowing difficulties. Many people with Stickler syndrome are very nearsighted (described as having high myopia) because of the shape of the eye. People with eye involvement are prone to increased pressure within the eye (ocular hypertension) which could lead to glaucoma and tearing or detachment of the light-sensitive retina of the eye (retinal detachment). Cataract may also present as an ocular complication associated with Stickler's Syndrome. The jelly-like substance within the eye (the vitreous humour) has a distinctive appearance in the types of Stickler syndrome associated with the COL2A1 and COL11A1 genes. As a result, regular appointments to a specialist ophthalmologist are advised.
=== Gelatin-based scaffolds === Gelatin is the denatured form of collagen. Gelatin possesses several advantages for tissue-engineering application: they attract fibroblasts, are non-immunogenic, easy to manipulate and boost the formation of epithelium. There are three types of gelatin-based scaffolds:
Sources: en.wikipedia.org
=== Typical views === Required projections can vary by country and hospital, although an erect posteroanterior (PA) projection is typically the first preference. If this is not possible, then an anteroposterior view will be taken. Further imaging depends on local protocols which is dependent on the hospital protocols, the availability of other imaging modalities and the preference of the image interpreter. In the UK, the standard chest radiography protocol is to take an erect posteroanterior view only and a lateral one only on request by a radiologist. In the US, chest radiography includes a PA and Lateral with the patient standing or sitting up. Special projections include an AP in cases where the image needs to be obtained stat (immediately) and with a portable device, particularly when a patient cannot be safely positioned upright. Lateral decubitus may be used for visualization of air-fluid levels if an upright image cannot be obtained. Anteroposterior (AP) Axial Lordotic projects the clavicles above the lung fields, allowing better visualization of the apices (which is extremely useful when looking for evidence of primary tuberculosis).
Consistent with the move away from questions of blame to questions of culture and ideology, American historians have also begun exploring the intersection between domestic U.S. political developments and the early years of Cold War outbreak. One such example is Thomas Borstelmann's 2003 work "The Cold War and the Color Line", which defines domestic racial discrimination after 1945 as a foreign as well as a domestic issue: America’s closest allies against the Soviet Union were colonial powers who had interests that needed to be balanced against those of the emerging 'Third World' in a diverse multiracial, anti-Communist alliance. Domestically, at the same time, U.S. racial reform was essential to preserve the national consensus needed to sustain the Cold War struggle.
=== Preclinical === AB-300 (AB300) – non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist AB-5006 (AX-5006) – Escherichia coli csgA protein aggregation inhibitor and gastrointestinal microbiome modulator [96] AEX-23 – orexin OX1 receptor agonist and α-synuclein aggregate/modulator [97] Afamelanotide ([Nle4,DPhe7]-α-MSH; CUV-1647; EPT-1647; Melanotan I; Melanotan; MT-I; Prenumbra; Scenesse) – melanocortin receptor agonist [98] Alpha-synuclein aggregation inhibitor (ACI-5755; morphomer α-synuclein) – α-synuclein inhibitor [99] BEBT-758 – RNA interference and α-synuclein expression inhibitor [100] Bevemipretide (SBT-272) – cardiolipin ligand and stabilizer [101] BSC-3301 – receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [102] BXQ-350 (SapC; SapC-DOPS; sphingolipid activator protein C) – sphingomyelin phosphodiesterase stimulant and sphingosine 1-phosphate stimulant [103] Cannabidiol (CBD) – cannabinoid receptor modulator and other actions [104] Carbon monoxide (CO; HBI-002) – heme oxygenase 1 modulator [105] CB-401 – amyloid β-protein modulator [106] CBT-102 – undefined mechanism of action [107] CJRB-301 (MRx-0005) – bacteria replacement and microbiome modulator [108] CJRB-302 (MRx-0029) – bacteria replacement and microbiome modulator [109] CK-0803 – regulatory T-lymphocyte replacement [110] CU-13001 – 15-lipoxygenase (15-LOX/ALOX15) inhibitor [111] EHP-102 (VCE-003.2) – cannabinoid CB2 receptor agonist and peroxisome proliferator-activated receptor alpha (PPARα) modulator (cannabigerol (CBG) derivative) [112] Estianeptine ((S)-tianeptine; TNX-4300) – peroxisome proliferator-activated receptor PPARβ/δ and PPARγ agonist [113] FHL-401 – toll-like receptor 2 antagonist [114] FHL-701 – interleukin-12 (IL-12) subunit p40 inhibitor [115] FKK-01PD (FKK-01PD; TGHW-01AP; apomorphine prodrug) – non-selective dopamine receptor agonist and other actions [116] HT-4403 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [117] IC-100 (ICCN-100) – various actions [118] KFRX-05 (BK-40195) – leucine-rich repeat kinase 2 (LRRK2) inhibitor and protein tyrosine kinase inhibitor [119] KP-405 – undefined mechanism of action [120] LB-P4 – bacteria replacement and microbiome modulator [121] Mbiotix – bacteria replacement and microbiome modulator [122] ML-021 – muscarinic acetylcholine M4 receptor antagonist [123] MP-201 – 2,4-dinitrophenol (DNP) prodrug and various actions [124] NB-003 – gene transference and parkin protein replacement [125] NB-129 – undefined mechanism of action [126] NLY-02 – glial cell inhibitor [127] NLY-03 – undefined mechanism of action [128] NNI-362 – 70 kDa ribosomal protein S6 kinase modulator [129] NRG-5051 – mitochondrial permeability transition pore inhibitor [130] PMN-442 – monoclonal antibody against α-synuclein [131] PP-003 – α-synuclein degrader [132] Research programme: 3100 programme - DigmBio/Daegu Catholic University – G protein-coupled receptor (GPCR) modulators [133] Research programme: enzyme targeted therapeutics - Nitrase Therapeutics – enzyme modulators and α-synuclein inhibitors [134] Research programme: neurodegenerative disease therapeutics - Caraway Therapeutics – autophagy stimulants and MCOLN1 stimulants [135] RGL-193 – undefined mechanism of action [136] ST-502 – gene therapy and α-synuclein genetic transcription inhibitor [137] Tomaralimab (NM-101; NM-102; NM-103; OPN-305) – monoclonal antibody against toll-like receptor 2 [138] Zervimesine (CT-1812; Elayta) – sigma σ2 receptor antagonist [139]
Sources: en.wikipedia.org
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。
胰岛素释放需要细胞内环腺苷酸与钙信号升高，同时依赖葡萄糖代谢产生的协同信号。血糖水平较低时协同信号不足，分泌增强有限。这一机制在降糖效果与低血糖风险之间提供了缓冲。
白蛋白结合是主要原因，它减少肾小球滤过并保护分子免受蛋白酶降解。序列修饰带来的酶解抵抗同样不可忽略，二者共同作用。脂肪链的疏水性还会影响组织分布，但其对总半衰期的贡献程度仍在研究之中。
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.